MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

B. Leticia Rodriguez; Don L. Gibbons

doi:10.1016/j.xcrm.2021.100506

MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

B. Leticia Rodriguez, Don L. Gibbons

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.

Original language	English (US)
Pages (from-to)	100506
Number of pages	1
Journal	Cell Reports Medicine
Volume	3
Issue number	1
DOIs	https://doi.org/10.1016/j.xcrm.2021.100506
State	Published - Jan 18 2022

ASJC Scopus subject areas

General Medicine

MD Anderson CCSG core facilities

Flow Cytometry and Cellular Imaging Facility

Access to Document

10.1016/j.xcrm.2021.100506

Cite this

@article{3a55acaa89244860acc325a4eb6cb17d,

title = "MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression",

abstract = "A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.",

author = "Rodriguez, {B. Leticia} and Gibbons, {Don L.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s).",

year = "2022",

month = jan,

day = "18",

doi = "10.1016/j.xcrm.2021.100506",

language = "English (US)",

volume = "3",

pages = "100506",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

AU - Rodriguez, B. Leticia

AU - Gibbons, Don L.

PY - 2022/1/18

Y1 - 2022/1/18

N2 - A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.

AB - A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85124679392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124679392&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2021.100506

DO - 10.1016/j.xcrm.2021.100506

M3 - Comment/debate

C2 - 35106515

AN - SCOPUS:85124679392

SN - 2666-3791

VL - 3

SP - 100506

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 1

ER -

MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this